{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:29:27Z","timestamp":1693787367634},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.acuro.2019.01.003","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T10:28:01Z","timestamp":1556879281000},"page":"300-304","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factores predictivos del s\u00edndrome de retirada de abiraterona"],"prefix":"10.1016","volume":"43","author":[{"given":"S.","family":"Almendros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Berenguer-Franc\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ferrer-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Boladeras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Guix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Guedea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2019.01.003_bib0075","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.acuro.2019.01.003_bib0080","doi-asserted-by":"crossref","first-page":"211-24","DOI":"10.1002\/pros.10360","article-title":"Development of prostate cancer treatment: the good news","volume":"58","author":"Denmeade","year":"2004","journal-title":"Prostate."},{"key":"10.1016\/j.acuro.2019.01.003_bib0085","unstructured":"Mottet N (Chair), Briers E (Patient Representative), van den Bergh RCN (Guidelines Associate), Bolla M, van Casteren NJ (Guidelines Associate), Cornford P, Culine S, Joniau S, Lam T, Mason MD, Matveev V, et al. European association of urology: Guidelines on Prostate Cancer. 2018. pp. 19-20. Disponible en: http:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/"},{"key":"10.1016\/j.acuro.2019.01.003_bib0090","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2019.01.003_bib0095","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuro.2019.01.003_bib0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2013.06.013","article-title":"A case of abiraterone acetate withdrawal","volume":"64","author":"Witjes","year":"2013","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2019.01.003_bib0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000341564","article-title":"Abiraterone acetate withdrawal syndrome: does it exist?","volume":"5","author":"Gauthier","year":"2012","journal-title":"Case Rep Oncol."},{"key":"10.1016\/j.acuro.2019.01.003_bib0110","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.clgc.2013.04.021","article-title":"Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?","volume":"11","author":"Caffo","year":"2013","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.acuro.2019.01.003_bib0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrurol.2014.345","article-title":"Switching and withdrawing hormonal agents for castration-resistant prostate cancer","volume":"12","author":"Lorente","year":"2015","journal-title":"Nat Rev Urol."},{"key":"10.1016\/j.acuro.2019.01.003_bib0120","first-page":"2669","article-title":"Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms","volume":"15","author":"Kato","year":"2018","journal-title":"Oncol Lett."},{"key":"10.1016\/j.acuro.2019.01.003_bib0125","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/bjc.2014.531","article-title":"Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone","volume":"111","author":"Lorente","year":"2014","journal-title":"Br J Cancer."},{"issue":"6 Suppl","key":"10.1016\/j.acuro.2019.01.003_bib0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/jco.2013.31.6_suppl.89","article-title":"Is there a withdrawal syndrome with abiraterone acetate (AA)?","volume":"31","author":"Albiges","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuro.2019.01.003_bib0135","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.urology.2013.07.029","article-title":"Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer","volume":"82","author":"Caffo","year":"2013","journal-title":"Urology."},{"issue":"2 Suppl","key":"10.1016\/j.acuro.2019.01.003_bib0140","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/jco.2016.34.2_suppl.324","article-title":"Long-term outcomes and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) showing abiraterone withdrawal syndrome (AWS) after docetaxel (DOC) treatment","volume":"34","author":"Caffo","year":"2016","journal-title":"J Clin Oncol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480619300336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480619300336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T06:46:20Z","timestamp":1561963580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480619300336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0210480619300336"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2019.01.003","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factores predictivos del s\u00edndrome de retirada de abiraterona","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2019.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}